Patterns of Cancer Genetic Testing: A Randomized Survey of Oregon Clinicians
Table 2
Summary data from the 2010 Oregon Health Care Provider Survey, by provider group.
(a) Demographic and practice characteristicsa,b.
PCPsc n (column %)d (95% CI)e
Naturopaths n (column %)d (95% CI)e
OB-GYNs n (column %)d (95% CI)e
Specialistsf n (column %)d (95% CI)e
Total
363 (30.0%)
216 (17.9%)
333 (27.5%)
297 (24.6%)
(27.5%–32.7%)
(15.8%–20.1%)
(25.1%–30.1%)
(22.2%–27.1%)
Mean age (years)
357 (48.0 yrs)
211 (43.5 yrs)
329 (47.8 yrs)
288 (47.6 yrs)
26 yrs–76 yrs
( 28 yrs–70 yrs)
27 yrs–80 yrs
27 yrs–79 yrs
Number of patients seen per week
<50
104 (28.8%)
185 (86.4%)
103 (31.0%)
127 (43.3%)
(24.4%–33.8%)
(81.2%–90.4%)
(26.3%–36.2%)
(37.8%–49.1%)
50–75
129 (35.7%)
25 (11.7%)
126 (38.0%)
121 (41.3%)
(31.0%–40.9%)
(8.0%–16.7%)
(32.9%–43.3%)
(35.8%–47.0%)
>75
127 (35.5%)
4 (1.9%)
103 (31.0%)
45 (15.4%)
(30.5%–40.4%)
(0.7%–4.9%)
(26.3%–36.2%)
(11.7%–20.0%)
Recommend BOCh screening to patients w/o cancer
394 (97.5%)
196 (92.0%)
326 (98.5%)
187 (63.6%)
(95.2%–98.7%)
(87.5%–95.0%)
(96.4%–99.4%)
(57.9%–68.9%)
Recommend CRCi screening to patients w/o cancer
355 (98.3%)
204 (95.8%)
316 (94.9%)
275 (93.5%)
(96.4%–99.3%)
(92.1%–97.8%)
(91.9%–96.8%)
(90.1%–95.8%)
Treat patients for BOCh
47 (13.1%)
79 (36.9%)
53 (16.1%)
172 (58.3%)
(10.0%–17.0%)
(30.7%–43.6%)
(12.5%–20.4%)
(52.6%–63.8%)
Treat patients for CRCi
48 (13.3%)
63 (29.4%)
0
241 (81.1%)
(10.1%–17.2%)
(23.7%–35.9%)
(76.3%–85.2%)
aCategory totals may be less than the total number of respondents, due to missing values.
bBolded estimates indicate significant findings.
cPCPs: primary care providers which include family physicians, internal medicine physicians, primary care nurse practitioners, and primary care physician assistants.
dThe column % reflects the percent responding within each practice category.
eCI: confidence interval.
fSpecialists consisted of surgeons, colorectal surgeons, general surgeons, gastroenterologists, oncologists, and gynecologic oncologists.
gRange in years.
hBOC: breast and ovarian cancer.
iCRC: colorectal cancer.
(b) Confidence in personal knowledge of medical geneticsa,b.
PCPsc (column %)d (95% CI)e
Naturopaths (column %)d (95% CI)e
OB-GYNs (column %)d (95% CI)e
Specialistsf (column %)d (95% CI)e
Confidence in personal knowledge of BOCg genetics
Not at all
111 (30.6%)
92 (42.6%)
23 (6.9%)
87 (30.0%)
(26.1%–35.5%)
(36.2%–49.3%)
(4.6%–10.2%)
(25.0%–35.5%)
Somewhat
188 (51.8%)
90 (41.7%)
132 (39.6%)
115 (39.7%)
(46.6%–56.9%)
(35.3%–48.4%)
(34.5%–45.0%)
(34.2%–45.4%)
Moderately/very
64 (17.6%)
34 (15.7%)
178 (53.5%)
88 (30.3%)
(14.1%–21.9%)
(11.5%–21.2%)
(48.1%–58.8%)
(25.3%–36.0%)
Confidence in personal knowledge of CRCh genetics
Not at all
110 (30.5%)
114 (52.8%)
77 (23.2%)
43 (11.3%)
(25.9–35.4)
(46.1–59.4)
(19.0–28.0)
(8.1–15.5)
Somewhat
190 (52.6%)
81 (37.5%)
176 (53.0%)
105 (36.0%)
(47.5%–57.7%)
(31.3%–44.2%)
(47.6%–58.3%)
(30.7%–41.6%)
Moderately/very
61 (16.9%)
21 (9.7%)
79 (23.8%)
154 (52.7%)
(13.4%–21.1%)
(6.4–14.5)
(19.5–28.7)
(47.0–58.4)
aCategory totals may be less than the total number of respondents, due to missing values.
bBolded estimates indicate significant findings.
cPCPs: primary care providers which include family physicians, internal medicine physicians, primary care nurse practitioners, and primary care physician assistants.
dThe column % reflects the percent responding within each practice category.
eCI: confidence interval.
fSpecialists consisted of surgeons, colorectal surgeons, general surgeons, gastroenterologists, oncologists, and gynecologic oncologists.
gBOC: breast and ovarian cancer.
hCRC: colorectal cancer.
(c) Referral of patients to a genetic specialista,b.
PCPsc (column %)d (95% CI)e
Naturopaths (column %)d (95% CI)e
OB-GYNs (column %)d (95% CI)e
Specialistsf (column %)d (95% CI)e
Referg patients w/o cancer to a genetic specialist for BRCA testing
111 (67.7%)
27 (50.0%)
225 (87.5%)
82 (75.9%)
(60.1%–74.4%)
(36.9%–63.1%)
(82.9%–91.1%)
(67.0%–83.1%)
Referg patients w/cancer to a genetic specialist for BRCA testing
19 (55.9%)
25 (53.2%)
40 (87.0%)
121 (75.6%)
(39.1%–71.5%)
(39.0%–66.9%)
(73.8%–94.0%)
(68.3%–81.7%)
Referg patients w/o cancer to a genetic specialist for MMR testing
30 (56.6%)
NAh
105 (91.3%)
122 (77.2%)
(43.0%–69.2%)
(84.5%–95.3%)
(70.0%–83.1%)
Referg patients w/cancer to a genetic specialist for MMR testing
NAh
NAh
131 (81.9%)
138 (78.0%)
(75.1%–87.1%)
(71.2%–83.5%)
aCategory totals may be less than the total number of respondents, due to missing values.
bBolded estimates indicate significant findings.
cPCPs: primary care providers which include family physicians, internal medicine physicians, primary care nurse practitioners, and primary care physician assistants.
dThe column % reflects the percent responding within each practice category.
eCI: confidence interval.
fSpecialists consisted of surgeons, colorectal surgeons, general surgeons, gastroenterologists, oncologists, and gynecologic oncologists.
gAmong providers who suspect a mutation, those who always or usually refer to a genetic specialist.
hUnable to report estimates due to small cell size.
